Dr. Lanzkron's major clinical research involves the study of sickle cell disease. Her primary research interest is to understand the barriers to care for adults with sickle cell disease. In 1998, the FDA approved the use of hydroxyurea to treat patients with sickle cell disease. This approval was based on a large clinical trial centered at Johns Hopkins. The use of hydroxyurea was predicted to decrease hospitalizations and the costs of care for those with sickle cell disease. Dr. Lanzkron's research has shown that despite the approval of hydroxyurea, the costs of caring for patients with sickle cell disease have increased significantly over the last seven years. Research is ongoing to identify the factors that limit access to care for this population.
Clinical Trial Keywords
Laurence B, George D, Woods D, Shosanya A, Katz RV, Lanzkron S, Diener-West M, Powe N. "The association between sickle cell disease and dental caries in African Americans." Spec Care Dentist. 2006 May-Jun;26(3):95-100.
Lanzkron S, Moliterno A, Norris EJ, Gould S, Segal J, Neurmberger E, Ness P. "Polymerized human hemoglobin use in acute chest syndrome: A case report." Transfusion. 2002 Nov;42(11):1422-7.
Shaughnessy PJ, Ririe DW, Ornstein DL, Kissack B, Bickford DJ, Molina R, Lanzkron S, Bachier C, Nanez A, LeMaistre CF. "Graft failure in a patient with systemic lupus erythematosus (SLE) treated with high-dose immunosuppression and autologous stem cell rescue." Bone Marrow Transplant. 2001 Jan;27(2):221-4.
Bachier CR, Gokmen E, Teale J, Lanzkron S, Childs C, Franklin W, Shpall E, Douville J, Weber S, Muller T, Armstrong D, Lemaistre CF. "Ex-vivo expansion of bone marrow progenitor cells for hematopoietic reconstitution following high dose chemotherapy for breast cancer." Exp Hem. 1999 Apr;27(4):615-23.
Lanzkron SM, Collector MI , Sharkis SJ. "Homing of long-term and short-term engrafting cells in vivo." Ann N Y Acad Sci. 1999 Apr 30;872:48-54; discussion 54-6.